Brief: Actinium Provides Regulatory Update On Planned BLA Filing And Future Plans For Iomab-B In The U.S.

Actinium Pharmaceuticals

05/08/2024 12:11

Aug 5 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM PROVIDES REGULATORY UPDATE ON PLANNED BLA FILING
AND
FUTURE PLANS FOR IOMAB-B IN THE U.S.
    * ACTINIUM PHARMACEUTICALS: FDA DETERMINED PHASE 3 SIERRA
TRIAL
NOT ADEQUATE TO SUPPORT BLA FILING FOR IOMAB-B
    * ACTINIUM PHARMACEUTICALS: ADDITIONAL HEAD-TO-HEAD
RANDOMIZED
CLINICAL TRIAL DEMONSTRATING OVERALL SURVIVAL BENEFIT WITH
IOMAB-B REQUIRED BY FDA
    * ACTINIUM PHARMACEUTICALS: WILL SEEK STRATEGIC PARTNER FOR
IOMAB-B IN U.S. FOLLOWING COMPLETION OF FDA INTERACTIONS

Source text for Eikon:  ID:nPn3Bwc6va 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))